Low dose Naltrexone for induction of remission in inflammatory bowel disease patients

• DOI: 10.1186/s12967-018-1427-5
• Publication Date: 2018-03-09T13:10:01Z
• Authors: Mitchell R. K. L....; Janine van der Gi...; Gwenny M. Fuhler; Alison de Lima; Maikel P. Peppele...; Cokkie van der Ent; C. Janneke van de...
• Keywords: Refractory (planetary science); Intestinal mucosa

Around 30% of patients with inflammatory bowel disease (IBD) are refractory to current IBD drugs or relapse over time. Novel treatments called for, and low dose Naltrexone (LDN) may provide a safe, easily accessible alternative treatment option for these patients. We investigated the potential LDN induce clinical response in therapy patients, its direct effects on epithelial barrier function. Patients not remission responding conventional were offered initiate as concomitant treatment. In total 47 prescribed followed prospectively 12 weeks. Where available, endoscopic data, serum biopsies collected. Further effect wound healing (scratch assay), cytokine production endoplasmic reticulum (ER) stress (GRP78 CHOP western blot analysis, immunohistochemistry) HCT116 CACO2 intestinal cells, human organoids patient samples. Low induced improvement 74.5%, 25.5% improved reduced ER by Tunicamycin, lipopolysaccharide bacteria barriers. Inflamed mucosa from showed high levels, which was treated LDN. Cytokine levels neither cells nor affected. directly improves function improving reducing mucosal levels. is effective could be considered